Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
KOOL's Cash-to-Debt is ranked higher than
96% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. KOOL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KOOL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.70
KOOL's Equity-to-Asset is ranked higher than
62% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. KOOL: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
KOOL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.26  Med: 0.81 Max: 0.91
Current: 0.7
0.26
0.91
Piotroski F-Score: 5
Altman Z-Score: -5.48
Beneish M-Score: -4.09
WACC vs ROIC
9.44%
-35.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -77.33
KOOL's Operating Margin % is ranked lower than
76% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. KOOL: -77.33 )
Ranked among companies with meaningful Operating Margin % only.
KOOL' s Operating Margin % Range Over the Past 10 Years
Min: -92.63  Med: -45.79 Max: -12.12
Current: -77.33
-92.63
-12.12
Net Margin % -297.49
KOOL's Net Margin % is ranked lower than
87% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. KOOL: -297.49 )
Ranked among companies with meaningful Net Margin % only.
KOOL' s Net Margin % Range Over the Past 10 Years
Min: -155.82  Med: -41.14 Max: -10.97
Current: -297.49
-155.82
-10.97
ROE % -118.69
KOOL's ROE % is ranked lower than
90% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. KOOL: -118.69 )
Ranked among companies with meaningful ROE % only.
KOOL' s ROE % Range Over the Past 10 Years
Min: -55.34  Med: -27.29 Max: -13.56
Current: -118.69
-55.34
-13.56
ROA % -81.63
KOOL's ROA % is ranked lower than
86% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. KOOL: -81.63 )
Ranked among companies with meaningful ROA % only.
KOOL' s ROA % Range Over the Past 10 Years
Min: -36.93  Med: -21.57 Max: -10.6
Current: -81.63
-36.93
-10.6
ROC (Joel Greenblatt) % -629.75
KOOL's ROC (Joel Greenblatt) % is ranked lower than
82% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. KOOL: -629.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KOOL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -359.15  Med: -136.59 Max: -36.5
Current: -629.75
-359.15
-36.5
3-Year Revenue Growth Rate -39.30
KOOL's 3-Year Revenue Growth Rate is ranked lower than
90% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. KOOL: -39.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KOOL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.3  Med: 1.8 Max: 80.6
Current: -39.3
-39.3
80.6
3-Year EBITDA Growth Rate 27.50
KOOL's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. KOOL: 27.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KOOL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60  Med: -6.1 Max: 270.1
Current: 27.5
-60
270.1
3-Year EPS without NRI Growth Rate 25.80
KOOL's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. KOOL: 25.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
KOOL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.3 Max: 278
Current: 25.8
0
278
GuruFocus has detected 2 Warning Signs with Cesca Therapeutics Inc $KOOL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KOOL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-13 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

KOOL Guru Trades in Q4 2015

Jim Simons 57,029 sh (New)
» More
Q1 2016

KOOL Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q2 2016

KOOL Guru Trades in Q2 2016

Jim Simons 30,635 sh (New)
» More
Q3 2016

KOOL Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3821
Compare:OTCPK:VICA, OTCPK:TLTFF, OTCPK:ZMSPF, OTCPK:LCTC, NAS:RWLK, NAS:MDVX, OTCPK:BSGM, NAS:MGCD, OTCPK:RMSL, OTCPK:DIZTF, OTCPK:MRLB, NAS:ETRM, OTCPK:QTVLF, AMEX:ELMD, OTCPK:FGCN, OTCPK:ARCRF, OTCPK:IMPZY, OTCPK:GCHIF, OTCPK:MRIC, OTCPK:SNWV » details
Traded in other countries:THRN.Germany,
Headquarter Location:USA
Cesca Therapeutics Inc is engaged in the development and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Cesca Therapeutics Inc formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.

Top Ranked Articles about Cesca Therapeutics Inc

CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair
Cesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International Precision Medicine Summit
Cesca Therapeutics Announces Senior Management Promotions
Cesca CLI Feasibility Study Published in Peer-Reviewed Journal

RANCHO CORDOVA, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the publication in a peer reviewed journal of data from its Critical Limb Ischemia (CLI) feasibility study utilizing the Company’s innovative point-of-care technology. The report was published in the “Stem Cells International” and is available online at https://www.hindawi.com/journals/sci/2017/4137626/ref/.
Results from the seventeen patient clinical study titled, “Safety and Effectiveness of Bone Marrow Cell Concentrate in the Treatment of Chronic Critical Limb Ischemia Utilizing a Rapid Point-of-Care System”, (the “Study”) were obtained using Cesca’s automated point-of-care technology. The single treatment procedure was performed at the patient’s bedside and took less than 60 minutes. The Study results showed significant improvement in wound healing, rest pain and six-minute walking distance, along with significant reduction in intermittent claudication pain following the treatment. Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX, a Cesca subsidiary and the corresponding author of the article commented, “We are targeting difficult to treat or life threatening conditions such as CLI with our autologous, cell-based therapies. We believe our innovative point-of-care cell processing systems, such as those used in the Study, can play an important role in optimizing the quality and quantity of target cells used to improve patient outcomes.” Dr. Xiaochun "Chris" Xu, Cesca's Interim CEO added, “We are pleased that the Study was recognized and published in a peer reviewed journal. The encouraging data highlights Cesca’s capability to develop effective automated cellular processing systems. We welcome strategic partners to help us further refine their use in larger clinical settings.” About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:  The SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.The CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.The AXP® System - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.The MXP® System - a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.The BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.Manual bag sets for use in the processing and cryogenic storage of cord blood. Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
[email protected]

Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
[email protected] / [email protected]

Read more...
Cesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers

Significant reduction in wound size observed in all treated patients using autologous platelet rich plasma

RANCHO CORDOVA, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers.
Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute. In the study, 24 patients with one wound/ulcer of varying etiology were treated with a single dose of PRP injections around the wound alongside a topical administration of autologous platelet gel. The process was completed at the patient’s bedside in a single session within 30 minutes. Healing of the wound/ulcer was observed in patients as early as 4 weeks after the PRP treatment with a mean healing time of 8.2 weeks ±1.9. All patients demonstrated healing of the wound/ulcer, with 17 (70.8%) patients showing a 90% reduction in wound size and 3 (12.5%) patients showing an 80-90% reduction over the course of the 24 week follow-up. The study also reported that there were no adverse events on the day of treatment or during the patient’s 24 week follow-up, demonstrating a good safety profile for the treatment of chronic non-healing wounds/ulcers. Dr. Venkatesh Ponemone, Study Director and Executive Director of TotipotentRX commented, “We are very pleased with the data from the study and believe that the use of PRP is a major breakthrough for the treatment of chronic non-healing wounds and ulcers. Using Cesca’s point-of-care platform, we are able to develop rapid cell based therapies at the patient’s bedside within 30 minutes significantly reducing the risk and costs associated with current standard of care treatments." “This peer-reviewed publication further validates our novel point-of-care platform for rapid cellular based therapies,” commented Dr. Chris Xu, Cesca's Interim Chief Executive Officer. “As we continue to strengthen our team and evaluate Cesca’s clinical pipeline, these additional data points serve as useful litmus tests to determine the most valuable growth opportunities for the company.” Chronic non-healing ulcers pose a significant health risk worldwide affecting an estimated 2-6 million people in the United States alone, and are a major cause of non-traumatic lower limb amputations. Despite a variety of standard of care treatments, many chronic ulcers fail to heal or persist for months/years and/or recur after healing, requiring additional advanced wound care therapies. Platelet Rich Plasma, however, has been a major breakthrough in the arena of vascular therapies allowing the use of a patient’s own body cells for wound/ulcer treatment, providing the necessary growth factors that enhance tissue healing. About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:   The SurgWerks™ System (in development) -- a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.The CellWerks™ System (in development) -- a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.The AutoXpress® System (AXP®) -- a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.The MarrowXpress™ System (MXP™) -- a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.The BioArchive® System -- an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.Manual bag sets for use in the processing and cryogenic storage of cord blood. Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
[email protected]

Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
[email protected] / [email protected]

Read more...
Cesca Therapeutics Announces Closing of $5 Million Revolving Line of Credit

RANCHO CORDOVA, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced that it has closed a revolving line of credit (“RLOC”) with Boyalife Investment Fund II, Inc.  The non-collaterized RLOC is for a term of five years and is generally drawable at Cesca’s discretion.  Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is company owned and controlled by the Company’s Interim Chief Executive Officer and Chairman of the Board.  Cesca also announced that it has set-up a wholly-owned subsidiary, ThermoGenesis Corp, to separately own and operate, and thereby strengthen its device business. The clinical development activities will remain with Cesca, the parent company.
“This RLOC with Boyalife gives us the financial resources to offer our expanding product pipeline to new and existing customers in the U.S. and international markets without having to dilute the Company’s stockholders at current market price” said Chris Xu, Cesca’s interim Chief Executive Officer, “Automation in cellular processing and point-of-care therapies is the core business for ThermoGenesis.  Setting up the device division in in its own entity is intended to enable Cesca to more effectively manage the device business’s performance and growth strategy.  Our goal is to make ThermoGenesis cash-flow neutral within next 12 months.” About Cesca Therapeutics Inc. Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. These include:   The SurgWerks™ System (in development) - a proprietary system comprised of the SurgWerks Processing Platform, including devices and analytics, and indication-specific SurgWerks Procedure Kits for use in regenerative stem cell therapy at the point-of-care for vascular and orthopedic diseases.
The CellWerks™ System (in development) - a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood.
The AutoXpress® System (AXP®) - a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood.
The MarrowXpress™ System (MXP™) - a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow.
The BioArchive® System - an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use.
Manual bag sets for use in the processing and cryogenic storage of cord blood.
Forward-Looking Statement The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Company Contact: Cesca Therapeutics Inc.
[email protected]

Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
[email protected] / [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.90
KOOL's PB Ratio is ranked higher than
88% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. KOOL: 0.90 )
Ranked among companies with meaningful PB Ratio only.
KOOL' s PB Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.35 Max: 6.7
Current: 0.9
0.16
6.7
PS Ratio 0.93
KOOL's PS Ratio is ranked higher than
79% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. KOOL: 0.93 )
Ranked among companies with meaningful PS Ratio only.
KOOL' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 1.58 Max: 19.2
Current: 0.93
0.36
19.2
EV-to-EBIT -0.97
KOOL's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. KOOL: -0.97 )
Ranked among companies with meaningful EV-to-EBIT only.
KOOL' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.6  Med: -2.8 Max: 0.5
Current: -0.97
-36.6
0.5
EV-to-EBITDA -1.01
KOOL's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. KOOL: -1.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
KOOL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.4  Med: -3.1 Max: 0.5
Current: -1.01
-39.4
0.5
Current Ratio 2.01
KOOL's Current Ratio is ranked lower than
61% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. KOOL: 2.01 )
Ranked among companies with meaningful Current Ratio only.
KOOL' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 4.62 Max: 16.85
Current: 2.01
1.14
16.85
Quick Ratio 1.50
KOOL's Quick Ratio is ranked lower than
59% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. KOOL: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
KOOL' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 3.25 Max: 15.88
Current: 1.5
0.8
15.88
Days Inventory 135.18
KOOL's Days Inventory is ranked lower than
52% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. KOOL: 135.18 )
Ranked among companies with meaningful Days Inventory only.
KOOL' s Days Inventory Range Over the Past 10 Years
Min: 119.78  Med: 152.7 Max: 181.75
Current: 135.18
119.78
181.75
Days Sales Outstanding 81.12
KOOL's Days Sales Outstanding is ranked lower than
61% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. KOOL: 81.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
KOOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.82  Med: 96.66 Max: 116.79
Current: 81.12
61.82
116.79
Days Payable 80.80
KOOL's Days Payable is ranked higher than
63% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. KOOL: 80.80 )
Ranked among companies with meaningful Days Payable only.
KOOL' s Days Payable Range Over the Past 10 Years
Min: 44.89  Med: 88.74 Max: 164.16
Current: 80.8
44.89
164.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.60
KOOL's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. KOOL: -53.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KOOL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.6  Med: -15.4 Max: 0
Current: -53.6
-53.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.59
KOOL's Price-to-Median-PS-Value is ranked higher than
83% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. KOOL: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KOOL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 4.44 Max: 15.43
Current: 0.59
0.34
15.43
Earnings Yield (Greenblatt) % -103.09
KOOL's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. KOOL: -103.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KOOL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -705.47  Med: 170.85 Max: 7391.6
Current: -103.09
-705.47
7391.6

More Statistics

Revenue (TTM) (Mil) $13.58
EPS (TTM) $ -9.07
Beta0.30
Short Percentage of Float17.10%
52-Week Range $1.85 - 7.39
Shares Outstanding (Mil)9.90

Analyst Estimate

Jun17 Jun18 Jun19 Jun20
Revenue (Mil $) 12 12 13 239
EPS ($) -1.18 -1.27 -1.27 3.84
EPS without NRI ($) -1.18 -1.27 -1.27 3.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Apr 11 2017 
Cesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International Preci Apr 07 2017 
Cesca Therapeutics Announces Senior Management Promotions Apr 03 2017 
Cesca CLI Feasibility Study Published in Peer-Reviewed Journal Mar 20 2017 
Cesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers Mar 15 2017 
Cesca Therapeutics Announces Closing of $5 Million Revolving Line of Credit Mar 13 2017 
Insiders Roundup: Vera Bradley Tops List Dec 30 2016 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem... Apr 11 2017
Cesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International... Apr 07 2017
Cesca Therapeutics Announces Senior Management Promotions Apr 03 2017
Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q2, 2017 By the Numbers : March 20, 2017 Mar 20 2017
Cesca CLI Feasibility Study Published in Peer-Reviewed Journal Mar 20 2017
Blog Coverage Cesca Therapeutics Announces Encouraging Results from a Study of its Treatment of... Mar 16 2017
Wednesday’s Biggest Biopharma Movers Mar 15 2017
Cesca Therapeutics' stock soars on heavy volume after 'encouraging' study results Mar 15 2017
Cesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers Mar 15 2017
Cesca Therapeutics Announces Closing of $5 Million Revolving Line of Credit Mar 13 2017
Cesca Therapeutics Strengthens Leadership Team and Board of Directors Feb 28 2017
Cesca Therapeutics Reports Second Quarter Fiscal 2017 Financial Results and Provides Business Update Feb 13 2017
Cesca Therapeutics to Announce Second Quarter Fiscal 2017 Results on February 13, 2017 Feb 09 2017
Insiders Keep Buying as Market Wraps on 2016: Tronic, Six Flags, Virtu Financial, Cesca Therapeutics... Jan 01 2017
Nvidia (NVDA) Can’t Shake Citron, Cempra (CEMP) Slammed by FDA Rejection, Plus 3 Other Major... Dec 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)